On March 10, 2026, verified physicians conducted one million consultations with OpenEvidence's artificial intelligence system in a single 24-hour period, the first time any medical AI platform has crossed that threshold. The company says a majority of practicing doctors in the United States now use it daily, and independent studies indicate more American physicians rely on it than on all other AI systems combined. In the span of roughly two years, a tool that didn't exist went from zero to embedded in the daily workflow of most of the country's doctors.
On March 10, 2026, verified physicians conducted one million consultations with OpenEvidence's artificial intelligence system in a single 24-hour period, the first time any medical AI platform has crossed that threshold. The company says a majority of practicing doctors in the United States now use it daily, and independent studies indicate more American physicians rely on it than on all other AI systems combined. In the span of roughly two years, a tool that didn't exist went from zero to embedded in the daily workflow of most of the country's doctors.
The milestone captures something larger than one company's growth: the rapid integration of AI into the core act of clinical reasoning. For decades, physicians relied on static reference tools like UpToDate and textbook knowledge to navigate an ever-expanding medical literature. OpenEvidence and its competitors are replacing that model with real-time, conversational AI grounded in peer-reviewed journals, fundamentally changing how clinical decisions get supported at scale. The questions now are about accuracy, liability, regulation, and whether the business model behind the tool—pharmaceutical advertising—creates conflicts that could undermine the trust physicians have placed in it.
